Menu
← Oncology Approval Tracker
FDA DECISION ·
Camcevi ETM
leuprolide mesylate · Foresee Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
A three-month subcutaneous depot for adults with advanced prostate cancer.
LAMPGEN ANALYSIS
Why it matters
The 21 mg formulation adds a quarterly administration schedule for leuprolide-based androgen deprivation.
What research teams should watch
Separate three-month and six-month ordering and recall schedules and confirm correct preparation before injection.
PRIMARY RECORDS